A Framework for Defining Evidentiary Criteria for Biomarker Qualification

John Wagner, M.D., Ph.D.

Senior Vice President, Head of Translational Research and Early Clinical, Takeda Pharmaceuticals





Goals of the Workshop

- To enhance clarity, predictability, and harmonization of the biomarker qualification process with a standard framework
- Improve the quality of BQ submissions to FDA
- Support FDA in the development of relevant Guidance(s) for Evidentiary Criteria in biomarker qualification





Biomarker qualification: Clarity, predictability,


harmonization

Guidance for Industry and FDA Staff

Qualification Process for Drug Development Tools

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> January 2014 Procedural





biomarkers

Biomarker Qualification Workshop Framework for Defining Evidentiary Criteria

Wireless Internet Passcode: BIOMARKERS












General Evidentiary Criteria Document Development







What does the framework provide?

- A clear set of steps needed for working toward Biomarker Qualification
- Identify key areas for defining biomarker need
- Specify and limit biomarker development focus to allow successful generation of appropriate evidence
- Provide consistent set of characteristics to describe and define the biomarker development program with the regulatory agency

Primary Assumption:

A clearly defined goal to the project will provide a better view of a path to ultimate drug development decision making and regulatory approval.


The framework provides a context for the discussion between sponsor and the agency.





Constructing a biomarker road map


The Proposed Five-Component Process







Need statement and context of use (COU)



	Elements of Contrat of Use	Examples	Notes
1	Mentity of the Nemador	Specific type of redelingle enters with questio imaging models in (e.g., left); (ECT, Deppley)	The term "Momenter" may refer to a single interaction with a single, appetite arrivant of teat, or one "computed Momenter" that he make up of some of individual Momenters considered in a stated eigenful or marks a single in appealing market.
		- Specific administration in physiologic fluid - Specific general himselve	A content of the applies to the companies blomarine as a solified entity. Individual companies of the companies blomarine do not have expense CODs solies they are intended for one or dead, alone blomarines.
9	Agent of the Normalian that is reasonal and the form in which is in small for histogrand interpretation	. Sparify again of subsignity findings such as basis member, witness, diseases, area, pariencie or other observate for (e.g., losser values).	Certain Nomerican may require orginal compressi determina much as the wholever of measurements time ("organicality.
		- A quelle comme of regarder	Specify the mode(s) of measurement when applicable (e.g., MSS, PET, and Triesmont).
		 Benerical of a malpix parally the quelled in relation in time (e.g., et a quelle time, study state, EEC, yet is airmed nitror yet instinue) 	Specify physiologic finitions or six of morphing may cont in the solution, given, error, when, when, even, $\langle W \rangle$
		. That is grain in conservant from or the iterated coins principal in $(q_{\perp},deng)$ which is a reference such as busines, bits about control, or normal range, at Σ -bits damps)	
,	havin oil departation of mind or million polici	- Initial quales a resp. of species	Portide the referred details resolution contentions the largest species, group
		. For each species, important characteristics $ x_{\mathcal{Q}}\rangle$ attrict, e.g.s, see, disease model, locality)	of species, or patients for which his marker qualification is single. Certain qualified his markers may apply specifically in a solute of institutionals or state of the species at solut. If no, this solute or strain should be quartied in the COL document.
		. Home and important description (e.g., up, resoluted by any disease, healthy procepts, disease plannings)	
	Propose of social drawing development	- Demonstration of classics of Leisting (Vendoring or Classics).	A ground description of this almost will sensity has pure (explicit or
		- Demonstration of organizating without perferring estimates histographology (Newslatinal Internations)	implicit) of the Dan Materians component of the CCCL. In stilling, a more precise description may conside in part of the Considera for Qualified Dan section.
		- Initial of opens regree	For many his markers this will be the histogram being minime or the histogram to measurement, and that its approach is then applied to make the decision described for discuss 16.
		- Diffration in closinal study artifacts conditional or resolutionism (e.g., diagnostic, seriolescoi, seriolescoi)	
•	Erroy development decrementations for applying the Microsofter	- Simulation - determination of two description schoom offset levels (ACCAL) for a genetic tracking when prior restricting smaller date to bloody (ACCAL), the subspace providency and the fact bloody (ACCAL), the subspace providency are described from the last day concludes management level providency consistent levels of the last anguarded control of the last an	Smarthe the detailmin is Fig. (includence when application of the Kennether Impact to the glaveledges growers. This indigit is a description of a type of profilem. One of one is fine, the objection and the which the Namester mobiles reading a decision.
		Chalcul: salection of description being hose of early (i.e., apply Warnshor in description) and the profess of the pr	
•	Integrated in, and decided before based in Name has	 Biomerica ironic alerea N indicata callular injuny in jurges 23. The NOVEL level in indice the exposure in which the algoric was charrood, and should be used in determining alerting does in clinical studies. 	This demons of the CCC interness defines the interpretation that in them- from management of the qualified interneties unlike offices of the interpretation on the drug development program.
		-Nicrositer irrela siere N indicate a glystologic response has consent, and the drug compressions in advanced the development	For composite hierarchies, the algorithm med in combine composite banks in a single interpretation; and the single interpretation in applical in decision medical and forms office on the single interpretation program.
		 To sistema of hierarchy levels show N indicated as significant ergen injury has constrained the first condition(s) with this profits can be schoosed for facility states. 	For some himselver, the decision (drug development action) record and the support of the decision of the proper and decreasions of the support of the decision of the support of the contract of the support of the decision and on more of these
		 The alasmost of times the relations to the state of a participation of the control and desire any continue in such patients 	demonic would'be continued in pleasing the appropriate condition of one (i.e., then may not be expense assumes the each of these elements in all costs).
		 Polissis with the marker banks greater than 10 are reported to have an analysis areas man of approximately Y or greater and should be associated in the clinical early 	
		Define with the biometric position for the presence of E term of text is CASA present that of an extreme requires in the granting the mechanism of solution X, and detail can be excelled in divined station (or 15 to be reaction to a response throughout such patients should have desiring discontinually	


- Need statement
 - The nature and extent of the need, drug development issue it addresses and target population
 - The major challenge(s) and unique aspects of these challenges the project is to address
 - The reasons and causes for the deficit being addressed
- COU statement concise description of how a biomarker is intended to be used in drug development
- COU simplified to only 2 elements:
 - O What class of biomarker is proposed and what information content would it provide?
 - What question is the biomarker intended to address? ("What is the biomarker's specific fitfor-purpose use?")





Examples of COU

BEST: identify likelihood of a clinical event



A prognostic marker for disease progression to be used as an inclusion criteria in a Phase 2 clinical trial of a novel drug to enrich for the likelihood of organ transplantation.

Clinical Trial Decision

BEST: response to an intervention or exposure.


A safety marker for organ toxicity to be used in a Phase 1 clinical trial of a novel drug in addition to a standard measure of organ toxicity to explore and refine the clinical trials stopping criteria.

Clinical Decision






Benefit and risk



- The benefit and risk profile, given that the COU is related to the biomarker's value to drug development or clinical trials, is assessed from the perspective of patients
- Benefit assessment
 - o What are the unmet needs of the population defined in the COU?
 - O What is the mortality and morbidity of the disease's natural history in the absence of treatment?
 - What is the severity of the disease or condition?
 - O What is the perceived benefit of the new biomarker vs. the current standard?
- Risk assessment
 - O What is the potential consequence or harm if the biomarker's performance is not aligned with expectations based on the COU?
 - What is the perceived incremental risk, new biomarker vs. current standard?
 - When in the drug development lifecycle is the biomarker intended use?
 - O What is the scope of the biomarker COU in terms of impacting drug development and regulatory review?

Examples of benefit and risk analyses




- Favorable benefit and risk profile lower level of evidence
 - Stratification of patients to ensure equal distribution of biomarker positive and biomarker negative individuals in the different arms of a clinical trial
 - If biomarker does not perform loss of resources but not patient safety
- Less favorable benefit and risk profile moderate level of evidence
 - o Safety biomarker used in addition to the traditional safety biomarkers
 - Degree of risk depends on the impact on decision-making in drug development and the risk to patients enrolled in the trials
- Challenging benefit and risk profile higher level of evidence
 - Surrogate endpoint
 - If the biomarker is not truly a surrogate endpoint for predicting clinical benefit, results invalid and inappropriate approval decisions made
 - Leads to potentially ineffective drugs marketed or patients denied access to effective therapy





Evidence map



- The evidence maps in this framework are inspired by, but not identical to, the one used by Altar et al. (2008)
- The COU choices made determine the overall relative level of benefit and risk
- Benefit and risk determined as a result of the COU in turn determines the levels of evidence needed to evaluate the biomarker for qualification
- The evidence acceptable for satisfying evidentiary criteria in some cases may be partially or entirely composed of retrospective, literature, or other "real world" types of evidence
- The levels of evidence required to qualify the marker can be described according to a series of variables

Evidence map

significance


0.111	101-1		n a'-11
Criterion	High	\Leftrightarrow	Minimal
(1) Assay ¹	Regulatory clearance or approval for marketing as a diagnostic	\longleftrightarrow	"Fit-for-purpose" validation with acceptable performance characteristics
(2a) Scientific Understanding ²	Causal biological links established between the disease, the intervention and the biomarker	\longleftrightarrow	Gaps in causal links and/or analyte identity
(2b) Scientific Understanding: Data source for comparison of disease to marker	Well designed with focused analysis on one or a small number of biomarkers	\longleftrightarrow	Biomarker discovery analysis from an exploratory trial or dataset
(3) Biological Performance Expectations ³	Low potential for false result	\longleftrightarrow	Improved performance over current state: [e.g., current standard if available]
(4) Types of data and samples proposed to establish qualification	Prospective double-blind control study or confirmed results in multiple independent data sets	\longleftrightarrow	Retrospective analysis of published results
(4a) Quality of clinical data source: Prospective study	Focused, randomized appropriately powered trial	\longleftrightarrow	Narrow subgroup of intended population, small, or exploratory trial with multiple measures and lack of correction for multiple comparisons
(4b) Quality of clinical data source: Retrospective study	Large population, well controlled combined/meta analysis or multiple studies independently confirming results	\longleftrightarrow	Small, or exploratory trial with multiple measure that is not appropriately powered for significance
(5a) ⁴ Statistical evidence of the relationship of the biomarker to clinical outcomes	Conclusive across multiple studies	\longleftrightarrow	Some evidence in the literature
(5b) Statistical evidence on the usefulness of the biomarker threshold for	Significantly better than current standard (could be in combination with the current standard)	\longleftrightarrow	Similar or slightly better than current standard





Analytical validation

- Accuracy
- Precision
- Analytical sensitivity
- Analytical specificity
- Reportable range
- Reference interval
- Reproducibility
- Stability




Very High Standard:	Minimum Requirements:			
	-			
Regulatory Marketing Approval	"Fit-for-Purpose" Validation			
as Diagnostic				
Parameters Evaluated During Validation				
Accuracy	Accuracy			
Precision	Precision			
Analytical sensitivity	Analytical sensitivity			
Analytical specificity	Analytical specificity			
Reportable range	Reportable range			
Reference interval	Reference interval			
Reproducibility	Other as required			
Stability				
Other as required				





The process is dynamic and interactive







Conclusion

- Alignment from multiple, diverse stakeholders
- Consistent, comprehensive, semi-quantitative parameters for biomarker qualification
- Greater degree of clarity, predictability, and harmonization
- Broadly applicable across multiple categories of biomarkers and COUs
- Since each category of biomarker and COU has unique factors to consider as part of the development process, multiple modules are proposed to address these more specific issues





Key Outcomes and Action Items from the Workshop

Main Findings

 Overall agreement on the validity of the framework and its utility to advance qualification of drug safety biomarkers

Action items

- ✓ Revise documents to support FDA Guidances (FNIH Biomarkers Consortium Website, STM publication)
 - "Mother" Guidance on evidentiary criteria for biomarker qualification (framework): conceptual, succinct, understandable
 - Baby Guidance #1 on applicability of framework to safety biomarkers, with specific examples of evidence based on case studies
 - Additional Baby Guidances (#2 and #3) on Analytical Validation and Statistics (may require additional workshops)
- ✓ Workshop on Analytical Validation (Duke-Margolis)
 - Generate a guidance that covers diagnostics and biomarker qualification
- ✓ Develop and pilot a 'safe harbor' database to serve as a repository for progressive qualification of biomarkers (C-Path Biomarker Data Repository)
- ✓ Apply similar approach used in this workshop to clarify the evidentiary standards needed to qualify surrogate (efficacy) endpoints (today)





Thanks to .com, .edu, .gov, and.org!

Evidentiary Criteria Working Group

- Linda Brady, NIMH/NIH
- Martha Brumfield, C-PATH
- Bill Chin, PhRMA
- Steve Hoffmann, FNIH
- Gary Kelloff, NCI/NIH
- Gabriela Lavezzari, Duke
- Chris Leptak, FDA
- Joe Menetski, FNIH
- Rajesh Ranganathan, PhRMA
- John-Michael Sauer, C-PATH
- Frank Sistare, Merck
- John Wagner, Takeda
- David Wholley, FNIH

Statistical Team

- Aloka Chakravarty, FDA
- Suzanne Hendrix, Pentara
- Lisa McShane, NCI/NIH
- Robin Mogg, Merck
- Klaus Romero, C-PATH
- Sue Jane Wan, FDA

Analytical Validation Team

- Amanda Baker, C-PATH
- Steven Piccoli, BMS
- John-Michael Sauer, C-PATH
- Diane Stephenson, C-PATH

Drug Induced Liver Injury Lead

• Jiri Aubrecht, Pfizer

Drug Induced Vascular Injury Lead

- Brad Enerson, Pfizer
- Michael Lawton, Pfizer
- Tanja Zabka, Genentech

Drug Induced Kidney Injury Lead

- Frank Sistare, Merck
- Steve Hoffmann, FNIH
- AND all those who attended the Workshop!



